Recursion Pharmaceuticals ($RXRX) Insider Trading & Smart Money Activity
Recursion Pharmaceuticals, Inc. ($RXRX) has 3 insider trades and 2 13F position changes on file. In the last 12 months on the open market, no insider bought and 3 insiders sold ($379.60K), net -$379.60K.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 3
- Net insider $ (12 mo)
- -$379.60K
- Congress trades (12 mo)
- 0
- 13F moves on file
- 2
- Analyst ratings on file
- 0
RXRX insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 1 · $12.60K | 0 / 0 | 2 / 0 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 2 · $367K | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All RXRX insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Robert HershbergDirector | Sell (Open-market sale) 10b5-1 | 25K sh | $125K | -17.3% | — | |||||
| Insider | Borgeson BlakeDirector | Sell (Open-market sale) 10b5-1 | 50K sh | $242K | -17.3% | — | |||||
| Insider | Namandje Bumpus | Sell (Open-market sale) 10b5-1 | 3.96K sh | $12.60K | +3.4% | -10.5% | — | ||||
| 13F | ARK Investment Management | Added | +2.90M sh | $126.67M | -9.5% | 0.0% | — | ||||
| 13F | ARK Investment Management | Added | +2.90M sh | $147.58M | -9.5% | 0.0% | Read |
1W / 1M / 6M = how RXRX moved from the trade or filing date.
Insider trading in RXRX: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Robert Hershberg | Director | 1 | -$125K | Oct 6, 2026 | |
| Borgeson Blake | Director | 1 | -$242K | Oct 6, 2026 | |
| Namandje Bumpus | 1 | -$12.60K | Jun 18, 2026 |
Institutions moving RXRX (13F)
Frequently asked questions
Are RXRX insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 3 insiders made 3 open-market sales worth $379.60K, a net -$379.60K.
What is the latest insider trade in RXRX?
Robert Hershberg, Director filed a sell (open-market sale) of 25K sh worth $125K on Oct 6, 2026.
Which institutions changed their RXRX positions?
Recent 13F filers moving the stock include ARK Investment Management.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.